Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients

BACKGROUND: Despite significant progress with antiprogrammed cell death protein 1 (PD-1) therapy, a substantial fraction of metastatic melanoma patients show upfront therapy resistance. Biomarkers for outcome are missing and the association of baseline immune function and clinical outcome remains to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gérard, Alexandre, Doyen, Jerome, Cremoni, Marion, Bailly, Laurent, Zorzi, Kevin, Ruetsch-Chelli, Caroline, Brglez, Vesna, Picard-Gauci, Alexandra, Troin, Laura, Esnault, Vincent L.M., Passeron, Thierry, Montaudié, Henri, Seitz-Polski, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183201/
https://www.ncbi.nlm.nih.gov/pubmed/34088741
http://dx.doi.org/10.1136/jitc-2021-002512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183201/
https://www.ncbi.nlm.nih.gov/pubmed/34088741
http://dx.doi.org/10.1136/jitc-2021-002512

Ejemplares similares